September 28, 2016

News Release

MSD K.K.
KYORIN Holdings, Inc.

MSD K.K. receives manufacturing and marketing approval for DESALEX® Tablets 5mg for treatment of allergic diseases

MSD K.K. (Head office: Chiyoda-ku, Tokyo; President: Jannie Oosthuizen) received on September 28 a manufacturing and marketing approval for DESALEX® Tablets 5mg (generic name: desloratadine) for the treatment of allergic diseases.

DESALEX® Tablets will be exclusively distributed by KYORIN Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo; President & CEO: Mitsutomo Miyashita), a wholly owned subsidiary of KYORIN Holdings, Inc. (Head office: Chiyoda-ku, Tokyo; President & CEO: Minoru Hogawa), under the exclusive distribution agreement with MSD's affiliate company.

DESALEX® Tablets is the second-generation antihistamine with new active ingredient. It is indicated for allergic rhinitis, urticaria, and pruritus associated with skin diseases (eczema, dermatitis, skin pruritus). It has been approved in more than 120 countries including the U.S. and Europe.

MSD will continue to demonstrate its commitment to patients and healthcare providers in broad therapeutic areas including respiratory and allergic therapeutic area through the manufacturing and marketing approval for DESALEX® Tablets.

Through distribution of this product, KYORIN Pharmaceutical will aim for further contribution to patients with allergic rhinitis and other diseases, and focus on increasing its presence in the respiratory and ear-nose-throat therapeutic fields. KYORIN Pharmaceutical has signed a memorandum of understanding regarding co-promotion of DESALEX® Tablets in the field of dermatology with Kaken Pharmaceutical Co., Ltd.

Contact	
MSD K.K. Communications Kitanomaru Square, 1-13-12, Kudan-kita, Chiyoda-ku, Tokyo 102-8667 TEL: 03-6272-1001 FAX: 03-6238-9136	KYORIN Holdings, Inc. Corporate Communications, President Office 6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo 101-8311 TEL: 03-3525-4707 FAX: 03-3525-4777

Related information

Second-generation antihistamine DESALEX® Tablets

Trade name	DESALEX® Tablets 5mg
Generic name	Desloratadine
Indications and usage	Allergic rhinitis, urticaria, and pruritus associated with skin diseases (eczema, dermatitis, skin pruritus)
Dosage and administration	Normally for children aged 12 or older and adults, orally administer 5mg of desloratadine once daily.
Application filed on	October 15, 2015
Approved on	September 28, 2016